Jiangrong Wang

Cervical screening faces challenges due to the declining quality of the routine cytology test, resulting in missed precancerous lesions and, consequently, increased cancer incidence in Sweden and other countries. Despite the introduction of HPV vaccination, screening remains essential, especially for unvaccinated populations and because of vaccine limitations. Our project addresses this issue by advancing cervical screening through the implementation of the WID-qCIN test, a promising DNA methylation marker which demonstrates superior accuracy in detecting precancerous lesions compared to cytology, as shown in our recent research. We aim to conduct a clinical trial to confirm its superiority over cytology and explore its extended uses for 1) potentially improved performance in conjunction with other screening indicators, 2) predicting the regression of moderate precancers in young women, and 3) adding value for older women who are about to exit the screening program with varied screening histories. During 2026-2029, the applicant will actively lead this project and establish a multidisciplinary team across epidemiology, gynaecology and molecular biology. By bridging research with clinical implementation, our project seeks to revolutionise cervical screening, mitigate the impact of the declining quality of cytology, and eventually accelerate the elimination of cervical cancer in Sweden and worldwide.

Vi arbetar för att förbättra screening för att mer effektivt förebygga livmoderhalscancer. Genom det nya testet, WID- qCIN, strävar vi efter att ersätta äldre metoder och ge mer pålitliga resultat. Testet kommer att bedömas i kliniska prövningar och anpassas för enkel användning i hemmet. Vårt mål är att göra screeningprocessen mer tillgänglig och skydda kvinnors hälsa bättre.